 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMBISOME increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"AMBISOME"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: AMBISOME: adverse_reactions: Metabolic & Nutritional Disorders Acidosis, amylase increased, hyperchloremia, hyperkalemia, hypermagnesemia, hyperphosphatemia, hyponatremia, hypophosphatemia, [0m
[31mhypoproteinemia, lactate dehydrogenase increased, nonprotein nitrogen [0m[1;31m([0m[31mNPN[0m[1;31m)[0m[31m increased, and respiratory alkalosis. Musculoskeletal System Arthralgia, bone pain, dystonia, myalgia, and rigors. Nervous [0m
[31mSystem Agitation, coma, convulsion, cough, depression, dysesthesia, dizziness, hallucinations, nervousness, paresthesia, somnolence, thinking abnormality, and tremor. Respiratory System Asthma, [0m
[31matelectasis, hemoptysis, hiccup, hyperventilation, influenza-like symptoms, lung edema, pharyngitis, pneumonia, respiratory insufficiency, respiratory failure, and sinusitis. AMBISOME: [0m
[31madverse_reactions: Skin & Appendages Alopecia, dry skin, herpes simplex, injection site inflammation, maculopapular rash, purpura, skin discoloration, skin disorder, skin ulcer, urticaria, and [0m
[31mvesiculobullous rash. Special Senses Conjunctivitis, dry eyes, and eye hemorrhage. Urogenital System Abnormal renal function, acute kidney failure, acute renal failure, dysuria, kidney failure, toxic [0m
[31mnephropathy, urinary incontinence, and vaginal hemorrhage. Post-marketing Experience The following infrequent adverse experiences have been reported in post-marketing surveillance, in addition to [0m
[31mthose mentioned above: angioedema, erythema, urticaria, bronchospasm, cyanosis/hypoventilation, pulmonary edema, agranulocytosis, hemorrhagic cystitis, and rhabdomyolysis. AMBISOME: adverse_reactions:[0m
[31mClinical Laboratory Values The effect of Am B isome on renal and hepatic function and on serum electrolytes was assessed from laboratory values measured repeatedly in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m. The frequency and[0m
[31mmagnitude of hepatic test abnormalities were similar in the Am B isome and amphotericin B groups. Nephrotoxicity was defined as creatinine values increasing [0m[1;31m100[0m[31m% or more over pretreatment levels in [0m
[31mpediatric patients, and creatinine values increasing [0m[1;31m100[0m[31m% or more over pretreatment levels in adult patients, provided the peak creatinine concentration was > [0m[1;31m1.2[0m[31m mg/dL. Hypokalemia was defined as [0m
[31mpotassium levels â‰¤ [0m[1;31m2.5[0m[31m mmol/L any time during treatment. AMBISOME: adverse_reactions: Incidence of nephrotoxicity, mean peak serum creatinine concentration, mean change from baseline in serum [0m
[31mcreatinine, and incidence of hypokalemia in the double-blind, randomized study were lower in the Am B isome group as summarized in the following table: Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m Laboratory Evidence of [0m
[31mNephrotoxicity AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m343[0m[31m [0m[1;31m344[0m[31m Nephrotoxicity [0m[1;31m64[0m[31m [0m[1;31m([0m[1;31m18.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m116[0m[31m [0m[1;31m([0m[1;31m33.7[0m[31m%[0m[1;31m)[0m[31m Mean peak creatinine [0m
[1;31m1.24[0m[31m mg/dL [0m[1;31m1.52[0m[31m mg/dL Mean change from baseline in creatinine [0m[1;31m0.48[0m[31m mg/dL [0m[1;31m0.77[0m[31m mg/dL Hypokalemia [0m[1;31m23[0m[31m [0m[1;31m([0m[1;31m6.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m40[0m[31m [0m[1;31m([0m[1;31m11.6[0m[31m%[0m[1;31m)[0m[31m The effect of Am B isome [0m[1;31m([0m[1;31m3[0m[31m mg/kg/day[0m[1;31m)[0m[31m vs. AMBISOME: adverse_reactions: [0m
[31mamphotericin B [0m[1;31m([0m[1;31m0.6[0m[31m mg/kg/day[0m[1;31m)[0m[31m on renal function in adult patients enrolled in this study is illustrated in the following figure: In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, the incidence of nephrotoxicity [0m
[31mas measured by increases of serum creatinine from baseline was significantly lower for patients administered Am B isome [0m[1;31m([0m[31mindividual dose groups and combined[0m[1;31m)[0m[31m compared with amphotericin B lipid [0m
[31mcomplex. Incidence of Nephrotoxicity Empirical Therapy Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m AmBisome Amphotericin B lipid complex [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m3[0m[31m mg/kg/day [0m[1;31m5[0m[31m mg/kg/day BOTH Total number of patients [0m[1;31m85[0m[31m [0m[1;31m81[0m[31m [0m[1;31m166[0m[31m [0m[1;31m78[0m[31m Number with [0m
[31mnephrotoxicity [0m[1;31m1.[0m[31m5X baseline serum creatinine value [0m[1;31m25[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m21[0m[31m [0m[1;31m([0m[1;31m25.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m27.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m62[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m 2X baseline serum creatinine value [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14.8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m33[0m[31m [0m
[1;31m([0m[1;31m42.3[0m[31m%[0m[1;31m)[0m[31m The following graph shows the average serum creatinine concentrations in the compassionate use study and shows that there is a drop from pretreatment concentrations for all patients, [0m
[31mespecially those with elevated [0m[1;31m([0m[31mgreater than [0m[1;31m1.7[0m[31m mg/dL[0m[1;31m)[0m[31m pretreatment creatinine concentrations. The incidence of nephrotoxicity in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m comparative trial in cryptococcal meningitis was lower[0m
[31min the Am B isome groups as shown in the following table: Laboratory Evidence of Nephrotoxicity Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: [0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m57.7[0m[31m%[0m[1;31m)[0m[31m Nausea [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m10.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m9.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m Vomiting [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m5.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m Hypertension [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m15.4[0m[31m%[0m[1;31m)[0m[31m [0m
[31mTachycardia [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m2.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m17.9[0m[31m%[0m[1;31m)[0m[31m Dyspnea [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m7.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m10.3[0m[31m%[0m[1;31m)[0m[31m Hypoxia [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m Day [0m[1;31m1[0m[31m body temperature increased [0m
[31mabove the temperature taken within [0m[1;31m1[0m[31m hour prior to infusion [0m[1;31m([0m[31mpreinfusion temperature[0m[1;31m)[0m[31m or above the lowest infusion value [0m[1;31m([0m[31mno preinfusion temperature recorded[0m[1;31m)[0m[31m. Patients were not administered [0m
[31mpremedications to prevent infusion-related reactions prior to the Day [0m[1;31m1[0m[31m study drug infusion. In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m, a randomized, double-blind, multicenter trial comparing Am B isome and amphotericin B [0m
[31mdeoxycholate as initial therapy for cryptococcal meningitis, premedications to prevent infusion-related reactions were permitted. Am B isome-treated patients had a lower incidence of fever, [0m
[31mchills/rigors and respiratory adverse events as summarized in the following table: Incidence of Infusion-Related Reactions Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m. [0m
[31mAMBISOME: adverse_reactions: [0m[1;31m7[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m86[0m[31m [0m[1;31m94[0m[31m [0m[1;31m87[0m[31m Patients with fever increase of [0m[1;31m>[0m[1;31m1[0m[31mÂ°C [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m28[0m[31m%[0m[1;31m)[0m[31m Patients with [0m
[31mchills/rigors [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m42[0m[31m [0m[1;31m([0m[1;31m48[0m[31m%[0m[1;31m)[0m[31m Patients with nausea [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m18[0m[31m [0m[1;31m([0m[1;31m20[0m[31m%[0m[1;31m)[0m[31m Patients with vomiting [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m Respiratory adverse events [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m There have been a few [0m
[31mreports of flushing, back pain with or without chest tightness, and chest pain associated with Am B isome administration; on occasion this has been severe. Where these symptoms were noted, the [0m
[31mreaction developed within a few minutes after the start of infusion and disappeared rapidly when the infusion was stopped. AMBISOME: adverse_reactions: The symptoms do not occur with every dose and [0m
[31musually do not recur on subsequent administrations when the infusion rate is slowed. Toxicity and Discontinuation of Dosing In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m, a significantly lower incidence of grade [0m[1;31m3[0m[31m or [0m[1;31m4[0m[31m toxicity [0m
[31mwas observed in the Am B isome group compared with the amphotericin B group. In addition, nearly three times as many patients administered amphotericin B required a reduction in dose due to toxicity [0m
[31mor discontinuation of study drug due to an infusion-related reaction compared with those administered Am B isome. In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a greater proportion of patients in the [0m
[31mamphotericin B lipid complex group discontinued the study drug due to an adverse event than in the Am B isome groups. AMBISOME: adverse_reactions: Less Common Adverse Events The following adverse [0m
[31mevents also have been reported in [0m[1;31m2[0m[31m% to [0m[1;31m10[0m[31m% of Am B isome-treated patients receiving chemotherapy or bone marrow transplantation, or who had HIV disease in six comparative, clinical trials: Body as a [0m
[31mWhole Abdomen enlarged, allergic reaction, cellulitis, cell-mediated immunological reaction, face edema, graft-versus-host disease, malaise, neck pain, and procedural complication. Cardiovascular [0m
[31mSystem Arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, cardiomegaly, hemorrhage, postural hypotension, valvular heart disease, vascular disorder, and vasodilatation [0m[1;31m([0m[31mflushing[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: [0m[1;31m4[0m[31m [0m[1;31m11.6[0m[31m [0m[1;31m16.3[0m[31m [0m[1;31m21.5[0m[31m [0m[1;31m20.9[0m[31m Digestive System Diarrhea Gastrointestinal hemorrhage Nausea Vomiting [0m[1;31m30.3[0m[31m [0m[1;31m9.9[0m[31m [0m[1;31m39.7[0m[31m [0m[1;31m31.8[0m[31m [0m[1;31m27.3[0m[31m [0m[1;31m11.3[0m[31m [0m[1;31m38.7[0m[31m [0m[1;31m43.9[0m[31m Metabolic and Nutritional [0m
[31mDisorders Alkaline phosphatase increased ALT [0m[1;31m([0m[31mSGPT[0m[1;31m)[0m[31m increased AST [0m[1;31m([0m[31mSGOT[0m[1;31m)[0m[31m increased Bilirubinemia BUN increased Creatinine increased Edema Hyperglycemia Hypernatremia Hypervolemia Hypocalcemia [0m
[31mHypokalemia Hypomagnesemia Peripheral edema [0m[1;31m22.2[0m[31m [0m[1;31m14.6[0m[31m [0m[1;31m12.8[0m[31m [0m[1;31m18.1[0m[31m [0m[1;31m21[0m[31m [0m[1;31m22.4[0m[31m [0m[1;31m14.3[0m[31m [0m[1;31m23[0m[31m [0m[1;31m4.1[0m[31m [0m[1;31m12.2[0m[31m [0m[1;31m18.4[0m[31m [0m[1;31m42.9[0m[31m [0m[1;31m20.4[0m[31m [0m[1;31m14.6[0m[31m [0m[1;31m19.2[0m[31m [0m[1;31m14[0m[31m [0m[1;31m12.8[0m[31m [0m[1;31m19[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m2[0m[31m [0m[1;31m31.1[0m[31m [0m[1;31m42.2[0m[31m [0m[1;31m14.8[0m[31m [0m[1;31m27.9[0m[31m [0m[1;31m11[0m[31m [0m[1;31m15.4[0m[31m [0m[1;31m20.9[0m[31m [0m[1;31m50.6[0m[31m [0m[1;31m25.6[0m[31m [0m
[1;31m17.2[0m[31m Nervous System Anxiety Confusion Headache Insomnia [0m[1;31m13.7[0m[31m [0m[1;31m11.4[0m[31m [0m[1;31m19.8[0m[31m [0m[1;31m17.2[0m[31m [0m[1;31m11[0m[31m [0m[1;31m13.4[0m[31m [0m[1;31m20.9[0m[31m [0m[1;31m14.2[0m[31m Respiratory System Cough increased Dyspnea Epistaxis Hypoxia Lung disorder Pleural effusion Rhinitis [0m[1;31m17.8[0m[31m [0m
[1;31m23[0m[31m [0m[1;31m14.9[0m[31m [0m[1;31m7.6[0m[31m [0m[1;31m17.8[0m[31m [0m[1;31m12.5[0m[31m [0m[1;31m11.1[0m[31m [0m[1;31m21.8[0m[31m [0m[1;31m29.1[0m[31m [0m[1;31m20.1[0m[31m [0m[1;31m14.8[0m[31m [0m[1;31m17.4[0m[31m [0m[1;31m9.6[0m[31m [0m[1;31m11[0m[31m Skin and Appendages Pruritus Rash Sweating [0m[1;31m10.8[0m[31m [0m[1;31m24.8[0m[31m [0m[1;31m7[0m[31m [0m[1;31m10.2[0m[31m [0m[1;31m24.4[0m[31m [0m[1;31m10[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m8[0m[31m Urogenital System Hematuria [0m[1;31m14[0m[31m [0m[1;31m14[0m[31m Am B [0m
[31misome was well tolerated. Am B isome had a lower incidence of chills, hypertension, hypotension, tachycardia, hypoxia, hypokalemia, and various events related to decreased kidney function as compared [0m
[31mto amphotericin B deoxycholate. In pediatric patients [0m[1;31m([0m[1;31m16[0m[31m years of age or less[0m[1;31m)[0m[31m in this double-blind study, Am B isome compared to amphotericin B deoxycholate, had a lower incidence of hypokalemia [0m
[1;31m([0m[1;31m37[0m[31m% versus [0m[1;31m55[0m[31m%[0m[1;31m)[0m[31m, chills [0m[1;31m([0m[1;31m29[0m[31m% versus [0m[1;31m68[0m[31m%[0m[1;31m)[0m[31m, vomiting [0m[1;31m([0m[1;31m27[0m[31m% versus [0m[1;31m55[0m[31m%[0m[1;31m)[0m[31m, and hypertension [0m[1;31m([0m[1;31m10[0m[31m% versus [0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m. AMBISOME: adverse_reactions: Similar trends, although with a somewhat lower incidence, were [0m
[31mobserved in open-label, randomized Study [0m[1;31m104[0m[31m-[0m[1;31m14[0m[31m involving [0m[1;31m205[0m[31m febrile neutropenic pediatric patients [0m[1;31m([0m[1;31m141[0m[31m treated with Am B isome and [0m[1;31m64[0m[31m treated with amphotericin B deoxycholate[0m[1;31m)[0m[31m. Pediatric patients [0m
[31mappear to have more tolerance than older individuals for the nephrotoxic effects of amphotericin B deoxycholate. The following adverse events are based on the experience of [0m[1;31m244[0m[31m patients [0m[1;31m([0m[1;31m202[0m[31m adult and[0m
[1;31m42[0m[31m pediatric patients[0m[1;31m)[0m[31m of whom [0m[1;31m85[0m[31m patients were treated with Am B isome [0m[1;31m3[0m[31m mg/kg, [0m[1;31m81[0m[31m patients were treated with Am B isome [0m[1;31m5[0m[31m mg/kg and [0m[1;31m78[0m[31m patients were treated with amphotericin B lipid complex [0m[1;31m5[0m[31m mg/kg[0m
[31min Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a randomized, double-blind, multi-center study in febrile, neutropenic patients. AMBISOME: adverse_reactions: Am B isome and amphotericin B lipid complex were infused over two [0m
[31mhours. The incidence of adverse events occurring in more than [0m[1;31m10[0m[31m% of subjects in one or more arms, regardless of relationship to study drug, are summarized in the following table: Empirical Therapy [0m
[31mStudy [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m Common Adverse Events Adverse Event by Body System AmBisome [0m[1;31m3[0m[31m mg/kg/day N = [0m[1;31m85[0m[31m % AmBisome [0m[1;31m5[0m[31m mg/kg/day N = [0m[1;31m81[0m[31m % Amphotericin B Lipid Complex [0m[1;31m5[0m[31m mg/kg/day N = [0m[1;31m78[0m[31m % Body as a Whole [0m
[31mAbdominal pain Asthenia Chills/rigors Sepsis Transfusion reaction [0m[1;31m12.9[0m[31m [0m[1;31m8.2[0m[31m [0m[1;31m40[0m[31m [0m[1;31m12.9[0m[31m [0m[1;31m10.6[0m[31m [0m[1;31m9.9[0m[31m [0m[1;31m6.2[0m[31m [0m[1;31m48.1[0m[31m [0m[1;31m7.4[0m[31m [0m[1;31m8.6[0m[31m [0m[1;31m11.5[0m[31m [0m[1;31m11.5[0m[31m [0m[1;31m89.7[0m[31m [0m[1;31m11.5[0m[31m [0m[1;31m5[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: clinical_studies: The following table presents a comparison of efficacy rates among immunocompetent and immunocompromised patients infected in the Mediterranean basin who had no [0m
[31mprior treatment or remote prior treatment for visceral leishmaniasis. Efficacy is expressed as both acute parasite clearance at the end of therapy [0m[1;31m([0m[31mEOT[0m[1;31m)[0m[31m and as overall success [0m[1;31m([0m[31mclearance with no [0m
[31mrelapse[0m[1;31m)[0m[31m during the follow-up period [0m[1;31m([0m[31mF/U[0m[1;31m)[0m[31m of greater than [0m[1;31m6[0m[31m months for immunocompetent and immunocompromised patients: AmBisome Efficacy in Visceral Leishmaniasis Immunocompetent Patients No. of [0m
[31mPatients Parasite [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Clearance at EOT Overall Success [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m at F/U [0m[1;31m87[0m[31m [0m[1;31m86[0m[31m/[0m[1;31m87[0m[31m [0m[1;31m([0m[1;31m98.9[0m[1;31m)[0m[31m [0m[1;31m83[0m[31m/[0m[1;31m86[0m[31m [0m[1;31m([0m[1;31m96.5[0m[1;31m)[0m[31m Immunocompromised Patients Regimen Total Dose Parasite [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Clearance at EOT Overall Success [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m at F/U [0m
[1;31m100[0m[31m mg/day X [0m[1;31m21[0m[31m days [0m[1;31m29[0m[31m-[0m[1;31m38[0m[31m. AMBISOME: clinical_studies: [0m[1;31m9[0m[31m mg/kg [0m[1;31m10[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m100[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m20[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m mg/kg/day, days [0m[1;31m1[0m[31m-[0m[1;31m5[0m[31m, and [0m[1;31m10[0m[31m, [0m[1;31m17[0m[31m, [0m[1;31m24[0m[31m, [0m[1;31m31[0m[31m, [0m[1;31m38[0m[31m [0m[1;31m40[0m[31m mg/kg [0m[1;31m8[0m[31m/[0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m88.9[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m/[0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m TOTAL [0m[1;31m18[0m[31m/[0m[1;31m19[0m[31m [0m[1;31m([0m[1;31m94.7[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m/[0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m11.8[0m[1;31m)[0m[31m When [0m
[31mfollowed for [0m[1;31m6[0m[31m months or more after treatment, the overall success rate among immunocompetent patients was [0m[1;31m96.5[0m[31m% and the overall success rate among immunocompromised patients was [0m[1;31m11.8[0m[31m% due to relapse [0m
[31min the majority of patients. While case reports have suggested there may be a role for long-term therapy to prevent relapses in HIV coinfected patients [0m[1;31m([0m[31mLopez-Dupla, et al. AMBISOME: clinical_studies:[0m
[31mJ Antimicrob Chemother [0m[1;31m1993[0m[31m; [0m[1;31m32[0m[31m: [0m[1;31m657[0m[31m-[0m[1;31m659[0m[1;31m)[0m[31m, there are no data to date documenting the efficacy or safety of repeat courses of Am B isome or of maintenance therapy with this drug among immunocompromised[0m
[31mpatients.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"AMBISOME"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does AMBISOME increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMBISOME increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"AMBISOME"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: AMBISOME: adverse_reactions: Metabolic & Nutritional Disorders Acidosis, amylase increased, hyperchloremia, hyperkalemia, hypermagnesemia, hyperphosphatemia, hyponatremia, hypophosphatemia, [0m
[31mhypoproteinemia, lactate dehydrogenase increased, nonprotein nitrogen [0m[1;31m([0m[31mNPN[0m[1;31m)[0m[31m increased, and respiratory alkalosis. Musculoskeletal System Arthralgia, bone pain, dystonia, myalgia, and rigors. Nervous [0m
[31mSystem Agitation, coma, convulsion, cough, depression, dysesthesia, dizziness, hallucinations, nervousness, paresthesia, somnolence, thinking abnormality, and tremor. Respiratory System Asthma, [0m
[31matelectasis, hemoptysis, hiccup, hyperventilation, influenza-like symptoms, lung edema, pharyngitis, pneumonia, respiratory insufficiency, respiratory failure, and sinusitis. AMBISOME: [0m
[31madverse_reactions: Skin & Appendages Alopecia, dry skin, herpes simplex, injection site inflammation, maculopapular rash, purpura, skin discoloration, skin disorder, skin ulcer, urticaria, and [0m
[31mvesiculobullous rash. Special Senses Conjunctivitis, dry eyes, and eye hemorrhage. Urogenital System Abnormal renal function, acute kidney failure, acute renal failure, dysuria, kidney failure, toxic [0m
[31mnephropathy, urinary incontinence, and vaginal hemorrhage. Post-marketing Experience The following infrequent adverse experiences have been reported in post-marketing surveillance, in addition to [0m
[31mthose mentioned above: angioedema, erythema, urticaria, bronchospasm, cyanosis/hypoventilation, pulmonary edema, agranulocytosis, hemorrhagic cystitis, and rhabdomyolysis. AMBISOME: adverse_reactions:[0m
[31mClinical Laboratory Values The effect of Am B isome on renal and hepatic function and on serum electrolytes was assessed from laboratory values measured repeatedly in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m. The frequency and[0m
[31mmagnitude of hepatic test abnormalities were similar in the Am B isome and amphotericin B groups. Nephrotoxicity was defined as creatinine values increasing [0m[1;31m100[0m[31m% or more over pretreatment levels in [0m
[31mpediatric patients, and creatinine values increasing [0m[1;31m100[0m[31m% or more over pretreatment levels in adult patients, provided the peak creatinine concentration was > [0m[1;31m1.2[0m[31m mg/dL. Hypokalemia was defined as [0m
[31mpotassium levels â‰¤ [0m[1;31m2.5[0m[31m mmol/L any time during treatment. AMBISOME: adverse_reactions: Incidence of nephrotoxicity, mean peak serum creatinine concentration, mean change from baseline in serum [0m
[31mcreatinine, and incidence of hypokalemia in the double-blind, randomized study were lower in the Am B isome group as summarized in the following table: Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m Laboratory Evidence of [0m
[31mNephrotoxicity AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m343[0m[31m [0m[1;31m344[0m[31m Nephrotoxicity [0m[1;31m64[0m[31m [0m[1;31m([0m[1;31m18.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m116[0m[31m [0m[1;31m([0m[1;31m33.7[0m[31m%[0m[1;31m)[0m[31m Mean peak creatinine [0m
[1;31m1.24[0m[31m mg/dL [0m[1;31m1.52[0m[31m mg/dL Mean change from baseline in creatinine [0m[1;31m0.48[0m[31m mg/dL [0m[1;31m0.77[0m[31m mg/dL Hypokalemia [0m[1;31m23[0m[31m [0m[1;31m([0m[1;31m6.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m40[0m[31m [0m[1;31m([0m[1;31m11.6[0m[31m%[0m[1;31m)[0m[31m The effect of Am B isome [0m[1;31m([0m[1;31m3[0m[31m mg/kg/day[0m[1;31m)[0m[31m vs. AMBISOME: adverse_reactions: [0m
[31mamphotericin B [0m[1;31m([0m[1;31m0.6[0m[31m mg/kg/day[0m[1;31m)[0m[31m on renal function in adult patients enrolled in this study is illustrated in the following figure: In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, the incidence of nephrotoxicity [0m
[31mas measured by increases of serum creatinine from baseline was significantly lower for patients administered Am B isome [0m[1;31m([0m[31mindividual dose groups and combined[0m[1;31m)[0m[31m compared with amphotericin B lipid [0m
[31mcomplex. Incidence of Nephrotoxicity Empirical Therapy Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m AmBisome Amphotericin B lipid complex [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m3[0m[31m mg/kg/day [0m[1;31m5[0m[31m mg/kg/day BOTH Total number of patients [0m[1;31m85[0m[31m [0m[1;31m81[0m[31m [0m[1;31m166[0m[31m [0m[1;31m78[0m[31m Number with [0m
[31mnephrotoxicity [0m[1;31m1.[0m[31m5X baseline serum creatinine value [0m[1;31m25[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m21[0m[31m [0m[1;31m([0m[1;31m25.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m27.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m62[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m 2X baseline serum creatinine value [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14.8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m33[0m[31m [0m
[1;31m([0m[1;31m42.3[0m[31m%[0m[1;31m)[0m[31m The following graph shows the average serum creatinine concentrations in the compassionate use study and shows that there is a drop from pretreatment concentrations for all patients, [0m
[31mespecially those with elevated [0m[1;31m([0m[31mgreater than [0m[1;31m1.7[0m[31m mg/dL[0m[1;31m)[0m[31m pretreatment creatinine concentrations. The incidence of nephrotoxicity in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m comparative trial in cryptococcal meningitis was lower[0m
[31min the Am B isome groups as shown in the following table: Laboratory Evidence of Nephrotoxicity Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: [0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m57.7[0m[31m%[0m[1;31m)[0m[31m Nausea [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m10.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m9.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m Vomiting [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m5.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m Hypertension [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m15.4[0m[31m%[0m[1;31m)[0m[31m [0m
[31mTachycardia [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m2.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m17.9[0m[31m%[0m[1;31m)[0m[31m Dyspnea [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m7.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m10.3[0m[31m%[0m[1;31m)[0m[31m Hypoxia [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m Day [0m[1;31m1[0m[31m body temperature increased [0m
[31mabove the temperature taken within [0m[1;31m1[0m[31m hour prior to infusion [0m[1;31m([0m[31mpreinfusion temperature[0m[1;31m)[0m[31m or above the lowest infusion value [0m[1;31m([0m[31mno preinfusion temperature recorded[0m[1;31m)[0m[31m. Patients were not administered [0m
[31mpremedications to prevent infusion-related reactions prior to the Day [0m[1;31m1[0m[31m study drug infusion. In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m, a randomized, double-blind, multicenter trial comparing Am B isome and amphotericin B [0m
[31mdeoxycholate as initial therapy for cryptococcal meningitis, premedications to prevent infusion-related reactions were permitted. Am B isome-treated patients had a lower incidence of fever, [0m
[31mchills/rigors and respiratory adverse events as summarized in the following table: Incidence of Infusion-Related Reactions Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m. [0m
[31mAMBISOME: adverse_reactions: [0m[1;31m7[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m86[0m[31m [0m[1;31m94[0m[31m [0m[1;31m87[0m[31m Patients with fever increase of [0m[1;31m>[0m[1;31m1[0m[31mÂ°C [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m28[0m[31m%[0m[1;31m)[0m[31m Patients with [0m
[31mchills/rigors [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m42[0m[31m [0m[1;31m([0m[1;31m48[0m[31m%[0m[1;31m)[0m[31m Patients with nausea [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m18[0m[31m [0m[1;31m([0m[1;31m20[0m[31m%[0m[1;31m)[0m[31m Patients with vomiting [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m Respiratory adverse events [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m There have been a few [0m
[31mreports of flushing, back pain with or without chest tightness, and chest pain associated with Am B isome administration; on occasion this has been severe. Where these symptoms were noted, the [0m
[31mreaction developed within a few minutes after the start of infusion and disappeared rapidly when the infusion was stopped. AMBISOME: adverse_reactions: The symptoms do not occur with every dose and [0m
[31musually do not recur on subsequent administrations when the infusion rate is slowed. Toxicity and Discontinuation of Dosing In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m, a significantly lower incidence of grade [0m[1;31m3[0m[31m or [0m[1;31m4[0m[31m toxicity [0m
[31mwas observed in the Am B isome group compared with the amphotericin B group. In addition, nearly three times as many patients administered amphotericin B required a reduction in dose due to toxicity [0m
[31mor discontinuation of study drug due to an infusion-related reaction compared with those administered Am B isome. In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a greater proportion of patients in the [0m
[31mamphotericin B lipid complex group discontinued the study drug due to an adverse event than in the Am B isome groups. AMBISOME: adverse_reactions: Less Common Adverse Events The following adverse [0m
[31mevents also have been reported in [0m[1;31m2[0m[31m% to [0m[1;31m10[0m[31m% of Am B isome-treated patients receiving chemotherapy or bone marrow transplantation, or who had HIV disease in six comparative, clinical trials: Body as a [0m
[31mWhole Abdomen enlarged, allergic reaction, cellulitis, cell-mediated immunological reaction, face edema, graft-versus-host disease, malaise, neck pain, and procedural complication. Cardiovascular [0m
[31mSystem Arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, cardiomegaly, hemorrhage, postural hypotension, valvular heart disease, vascular disorder, and vasodilatation [0m[1;31m([0m[31mflushing[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: [0m[1;31m4[0m[31m [0m[1;31m11.6[0m[31m [0m[1;31m16.3[0m[31m [0m[1;31m21.5[0m[31m [0m[1;31m20.9[0m[31m Digestive System Diarrhea Gastrointestinal hemorrhage Nausea Vomiting [0m[1;31m30.3[0m[31m [0m[1;31m9.9[0m[31m [0m[1;31m39.7[0m[31m [0m[1;31m31.8[0m[31m [0m[1;31m27.3[0m[31m [0m[1;31m11.3[0m[31m [0m[1;31m38.7[0m[31m [0m[1;31m43.9[0m[31m Metabolic and Nutritional [0m
[31mDisorders Alkaline phosphatase increased ALT [0m[1;31m([0m[31mSGPT[0m[1;31m)[0m[31m increased AST [0m[1;31m([0m[31mSGOT[0m[1;31m)[0m[31m increased Bilirubinemia BUN increased Creatinine increased Edema Hyperglycemia Hypernatremia Hypervolemia Hypocalcemia [0m
[31mHypokalemia Hypomagnesemia Peripheral edema [0m[1;31m22.2[0m[31m [0m[1;31m14.6[0m[31m [0m[1;31m12.8[0m[31m [0m[1;31m18.1[0m[31m [0m[1;31m21[0m[31m [0m[1;31m22.4[0m[31m [0m[1;31m14.3[0m[31m [0m[1;31m23[0m[31m [0m[1;31m4.1[0m[31m [0m[1;31m12.2[0m[31m [0m[1;31m18.4[0m[31m [0m[1;31m42.9[0m[31m [0m[1;31m20.4[0m[31m [0m[1;31m14.6[0m[31m [0m[1;31m19.2[0m[31m [0m[1;31m14[0m[31m [0m[1;31m12.8[0m[31m [0m[1;31m19[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m2[0m[31m [0m[1;31m31.1[0m[31m [0m[1;31m42.2[0m[31m [0m[1;31m14.8[0m[31m [0m[1;31m27.9[0m[31m [0m[1;31m11[0m[31m [0m[1;31m15.4[0m[31m [0m[1;31m20.9[0m[31m [0m[1;31m50.6[0m[31m [0m[1;31m25.6[0m[31m [0m
[1;31m17.2[0m[31m Nervous System Anxiety Confusion Headache Insomnia [0m[1;31m13.7[0m[31m [0m[1;31m11.4[0m[31m [0m[1;31m19.8[0m[31m [0m[1;31m17.2[0m[31m [0m[1;31m11[0m[31m [0m[1;31m13.4[0m[31m [0m[1;31m20.9[0m[31m [0m[1;31m14.2[0m[31m Respiratory System Cough increased Dyspnea Epistaxis Hypoxia Lung disorder Pleural effusion Rhinitis [0m[1;31m17.8[0m[31m [0m
[1;31m23[0m[31m [0m[1;31m14.9[0m[31m [0m[1;31m7.6[0m[31m [0m[1;31m17.8[0m[31m [0m[1;31m12.5[0m[31m [0m[1;31m11.1[0m[31m [0m[1;31m21.8[0m[31m [0m[1;31m29.1[0m[31m [0m[1;31m20.1[0m[31m [0m[1;31m14.8[0m[31m [0m[1;31m17.4[0m[31m [0m[1;31m9.6[0m[31m [0m[1;31m11[0m[31m Skin and Appendages Pruritus Rash Sweating [0m[1;31m10.8[0m[31m [0m[1;31m24.8[0m[31m [0m[1;31m7[0m[31m [0m[1;31m10.2[0m[31m [0m[1;31m24.4[0m[31m [0m[1;31m10[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m8[0m[31m Urogenital System Hematuria [0m[1;31m14[0m[31m [0m[1;31m14[0m[31m Am B [0m
[31misome was well tolerated. Am B isome had a lower incidence of chills, hypertension, hypotension, tachycardia, hypoxia, hypokalemia, and various events related to decreased kidney function as compared [0m
[31mto amphotericin B deoxycholate. In pediatric patients [0m[1;31m([0m[1;31m16[0m[31m years of age or less[0m[1;31m)[0m[31m in this double-blind study, Am B isome compared to amphotericin B deoxycholate, had a lower incidence of hypokalemia [0m
[1;31m([0m[1;31m37[0m[31m% versus [0m[1;31m55[0m[31m%[0m[1;31m)[0m[31m, chills [0m[1;31m([0m[1;31m29[0m[31m% versus [0m[1;31m68[0m[31m%[0m[1;31m)[0m[31m, vomiting [0m[1;31m([0m[1;31m27[0m[31m% versus [0m[1;31m55[0m[31m%[0m[1;31m)[0m[31m, and hypertension [0m[1;31m([0m[1;31m10[0m[31m% versus [0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m. AMBISOME: adverse_reactions: Similar trends, although with a somewhat lower incidence, were [0m
[31mobserved in open-label, randomized Study [0m[1;31m104[0m[31m-[0m[1;31m14[0m[31m involving [0m[1;31m205[0m[31m febrile neutropenic pediatric patients [0m[1;31m([0m[1;31m141[0m[31m treated with Am B isome and [0m[1;31m64[0m[31m treated with amphotericin B deoxycholate[0m[1;31m)[0m[31m. Pediatric patients [0m
[31mappear to have more tolerance than older individuals for the nephrotoxic effects of amphotericin B deoxycholate. The following adverse events are based on the experience of [0m[1;31m244[0m[31m patients [0m[1;31m([0m[1;31m202[0m[31m adult and[0m
[1;31m42[0m[31m pediatric patients[0m[1;31m)[0m[31m of whom [0m[1;31m85[0m[31m patients were treated with Am B isome [0m[1;31m3[0m[31m mg/kg, [0m[1;31m81[0m[31m patients were treated with Am B isome [0m[1;31m5[0m[31m mg/kg and [0m[1;31m78[0m[31m patients were treated with amphotericin B lipid complex [0m[1;31m5[0m[31m mg/kg[0m
[31min Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a randomized, double-blind, multi-center study in febrile, neutropenic patients. AMBISOME: adverse_reactions: Am B isome and amphotericin B lipid complex were infused over two [0m
[31mhours. The incidence of adverse events occurring in more than [0m[1;31m10[0m[31m% of subjects in one or more arms, regardless of relationship to study drug, are summarized in the following table: Empirical Therapy [0m
[31mStudy [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m Common Adverse Events Adverse Event by Body System AmBisome [0m[1;31m3[0m[31m mg/kg/day N = [0m[1;31m85[0m[31m % AmBisome [0m[1;31m5[0m[31m mg/kg/day N = [0m[1;31m81[0m[31m % Amphotericin B Lipid Complex [0m[1;31m5[0m[31m mg/kg/day N = [0m[1;31m78[0m[31m % Body as a Whole [0m
[31mAbdominal pain Asthenia Chills/rigors Sepsis Transfusion reaction [0m[1;31m12.9[0m[31m [0m[1;31m8.2[0m[31m [0m[1;31m40[0m[31m [0m[1;31m12.9[0m[31m [0m[1;31m10.6[0m[31m [0m[1;31m9.9[0m[31m [0m[1;31m6.2[0m[31m [0m[1;31m48.1[0m[31m [0m[1;31m7.4[0m[31m [0m[1;31m8.6[0m[31m [0m[1;31m11.5[0m[31m [0m[1;31m11.5[0m[31m [0m[1;31m89.7[0m[31m [0m[1;31m11.5[0m[31m [0m[1;31m5[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: clinical_studies: The following table presents a comparison of efficacy rates among immunocompetent and immunocompromised patients infected in the Mediterranean basin who had no [0m
[31mprior treatment or remote prior treatment for visceral leishmaniasis. Efficacy is expressed as both acute parasite clearance at the end of therapy [0m[1;31m([0m[31mEOT[0m[1;31m)[0m[31m and as overall success [0m[1;31m([0m[31mclearance with no [0m
[31mrelapse[0m[1;31m)[0m[31m during the follow-up period [0m[1;31m([0m[31mF/U[0m[1;31m)[0m[31m of greater than [0m[1;31m6[0m[31m months for immunocompetent and immunocompromised patients: AmBisome Efficacy in Visceral Leishmaniasis Immunocompetent Patients No. of [0m
[31mPatients Parasite [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Clearance at EOT Overall Success [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m at F/U [0m[1;31m87[0m[31m [0m[1;31m86[0m[31m/[0m[1;31m87[0m[31m [0m[1;31m([0m[1;31m98.9[0m[1;31m)[0m[31m [0m[1;31m83[0m[31m/[0m[1;31m86[0m[31m [0m[1;31m([0m[1;31m96.5[0m[1;31m)[0m[31m Immunocompromised Patients Regimen Total Dose Parasite [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Clearance at EOT Overall Success [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m at F/U [0m
[1;31m100[0m[31m mg/day X [0m[1;31m21[0m[31m days [0m[1;31m29[0m[31m-[0m[1;31m38[0m[31m. AMBISOME: clinical_studies: [0m[1;31m9[0m[31m mg/kg [0m[1;31m10[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m100[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m20[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m mg/kg/day, days [0m[1;31m1[0m[31m-[0m[1;31m5[0m[31m, and [0m[1;31m10[0m[31m, [0m[1;31m17[0m[31m, [0m[1;31m24[0m[31m, [0m[1;31m31[0m[31m, [0m[1;31m38[0m[31m [0m[1;31m40[0m[31m mg/kg [0m[1;31m8[0m[31m/[0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m88.9[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m/[0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m TOTAL [0m[1;31m18[0m[31m/[0m[1;31m19[0m[31m [0m[1;31m([0m[1;31m94.7[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m/[0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m11.8[0m[1;31m)[0m[31m When [0m
[31mfollowed for [0m[1;31m6[0m[31m months or more after treatment, the overall success rate among immunocompetent patients was [0m[1;31m96.5[0m[31m% and the overall success rate among immunocompromised patients was [0m[1;31m11.8[0m[31m% due to relapse [0m
[31min the majority of patients. While case reports have suggested there may be a role for long-term therapy to prevent relapses in HIV coinfected patients [0m[1;31m([0m[31mLopez-Dupla, et al. AMBISOME: clinical_studies:[0m
[31mJ Antimicrob Chemother [0m[1;31m1993[0m[31m; [0m[1;31m32[0m[31m: [0m[1;31m657[0m[31m-[0m[1;31m659[0m[1;31m)[0m[31m, there are no data to date documenting the efficacy or safety of repeat courses of Am B isome or of maintenance therapy with this drug among immunocompromised[0m
[31mpatients.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMBISOME increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"AMBISOME"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does AMBISOME increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMBISOME increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"AMBISOME"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: AMBISOME: adverse_reactions: Metabolic & Nutritional Disorders Acidosis, amylase increased, hyperchloremia, hyperkalemia, hypermagnesemia, hyperphosphatemia, hyponatremia, hypophosphatemia, [0m
[31mhypoproteinemia, lactate dehydrogenase increased, nonprotein nitrogen [0m[1;31m([0m[31mNPN[0m[1;31m)[0m[31m increased, and respiratory alkalosis. Musculoskeletal System Arthralgia, bone pain, dystonia, myalgia, and rigors. Nervous [0m
[31mSystem Agitation, coma, convulsion, cough, depression, dysesthesia, dizziness, hallucinations, nervousness, paresthesia, somnolence, thinking abnormality, and tremor. Respiratory System Asthma, [0m
[31matelectasis, hemoptysis, hiccup, hyperventilation, influenza-like symptoms, lung edema, pharyngitis, pneumonia, respiratory insufficiency, respiratory failure, and sinusitis. AMBISOME: [0m
[31madverse_reactions: Skin & Appendages Alopecia, dry skin, herpes simplex, injection site inflammation, maculopapular rash, purpura, skin discoloration, skin disorder, skin ulcer, urticaria, and [0m
[31mvesiculobullous rash. Special Senses Conjunctivitis, dry eyes, and eye hemorrhage. Urogenital System Abnormal renal function, acute kidney failure, acute renal failure, dysuria, kidney failure, toxic [0m
[31mnephropathy, urinary incontinence, and vaginal hemorrhage. Post-marketing Experience The following infrequent adverse experiences have been reported in post-marketing surveillance, in addition to [0m
[31mthose mentioned above: angioedema, erythema, urticaria, bronchospasm, cyanosis/hypoventilation, pulmonary edema, agranulocytosis, hemorrhagic cystitis, and rhabdomyolysis. AMBISOME: adverse_reactions:[0m
[31mClinical Laboratory Values The effect of Am B isome on renal and hepatic function and on serum electrolytes was assessed from laboratory values measured repeatedly in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m. The frequency and[0m
[31mmagnitude of hepatic test abnormalities were similar in the Am B isome and amphotericin B groups. Nephrotoxicity was defined as creatinine values increasing [0m[1;31m100[0m[31m% or more over pretreatment levels in [0m
[31mpediatric patients, and creatinine values increasing [0m[1;31m100[0m[31m% or more over pretreatment levels in adult patients, provided the peak creatinine concentration was > [0m[1;31m1.2[0m[31m mg/dL. Hypokalemia was defined as [0m
[31mpotassium levels â‰¤ [0m[1;31m2.5[0m[31m mmol/L any time during treatment. AMBISOME: adverse_reactions: Incidence of nephrotoxicity, mean peak serum creatinine concentration, mean change from baseline in serum [0m
[31mcreatinine, and incidence of hypokalemia in the double-blind, randomized study were lower in the Am B isome group as summarized in the following table: Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m Laboratory Evidence of [0m
[31mNephrotoxicity AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m343[0m[31m [0m[1;31m344[0m[31m Nephrotoxicity [0m[1;31m64[0m[31m [0m[1;31m([0m[1;31m18.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m116[0m[31m [0m[1;31m([0m[1;31m33.7[0m[31m%[0m[1;31m)[0m[31m Mean peak creatinine [0m
[1;31m1.24[0m[31m mg/dL [0m[1;31m1.52[0m[31m mg/dL Mean change from baseline in creatinine [0m[1;31m0.48[0m[31m mg/dL [0m[1;31m0.77[0m[31m mg/dL Hypokalemia [0m[1;31m23[0m[31m [0m[1;31m([0m[1;31m6.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m40[0m[31m [0m[1;31m([0m[1;31m11.6[0m[31m%[0m[1;31m)[0m[31m The effect of Am B isome [0m[1;31m([0m[1;31m3[0m[31m mg/kg/day[0m[1;31m)[0m[31m vs. AMBISOME: adverse_reactions: [0m
[31mamphotericin B [0m[1;31m([0m[1;31m0.6[0m[31m mg/kg/day[0m[1;31m)[0m[31m on renal function in adult patients enrolled in this study is illustrated in the following figure: In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, the incidence of nephrotoxicity [0m
[31mas measured by increases of serum creatinine from baseline was significantly lower for patients administered Am B isome [0m[1;31m([0m[31mindividual dose groups and combined[0m[1;31m)[0m[31m compared with amphotericin B lipid [0m
[31mcomplex. Incidence of Nephrotoxicity Empirical Therapy Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m AmBisome Amphotericin B lipid complex [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m3[0m[31m mg/kg/day [0m[1;31m5[0m[31m mg/kg/day BOTH Total number of patients [0m[1;31m85[0m[31m [0m[1;31m81[0m[31m [0m[1;31m166[0m[31m [0m[1;31m78[0m[31m Number with [0m
[31mnephrotoxicity [0m[1;31m1.[0m[31m5X baseline serum creatinine value [0m[1;31m25[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m21[0m[31m [0m[1;31m([0m[1;31m25.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m27.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m62[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m 2X baseline serum creatinine value [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14.8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m33[0m[31m [0m
[1;31m([0m[1;31m42.3[0m[31m%[0m[1;31m)[0m[31m The following graph shows the average serum creatinine concentrations in the compassionate use study and shows that there is a drop from pretreatment concentrations for all patients, [0m
[31mespecially those with elevated [0m[1;31m([0m[31mgreater than [0m[1;31m1.7[0m[31m mg/dL[0m[1;31m)[0m[31m pretreatment creatinine concentrations. The incidence of nephrotoxicity in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m comparative trial in cryptococcal meningitis was lower[0m
[31min the Am B isome groups as shown in the following table: Laboratory Evidence of Nephrotoxicity Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: [0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m57.7[0m[31m%[0m[1;31m)[0m[31m Nausea [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m10.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m9.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m Vomiting [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m5.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m Hypertension [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m15.4[0m[31m%[0m[1;31m)[0m[31m [0m
[31mTachycardia [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m2.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m17.9[0m[31m%[0m[1;31m)[0m[31m Dyspnea [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m7.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m10.3[0m[31m%[0m[1;31m)[0m[31m Hypoxia [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m Day [0m[1;31m1[0m[31m body temperature increased [0m
[31mabove the temperature taken within [0m[1;31m1[0m[31m hour prior to infusion [0m[1;31m([0m[31mpreinfusion temperature[0m[1;31m)[0m[31m or above the lowest infusion value [0m[1;31m([0m[31mno preinfusion temperature recorded[0m[1;31m)[0m[31m. Patients were not administered [0m
[31mpremedications to prevent infusion-related reactions prior to the Day [0m[1;31m1[0m[31m study drug infusion. In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m, a randomized, double-blind, multicenter trial comparing Am B isome and amphotericin B [0m
[31mdeoxycholate as initial therapy for cryptococcal meningitis, premedications to prevent infusion-related reactions were permitted. Am B isome-treated patients had a lower incidence of fever, [0m
[31mchills/rigors and respiratory adverse events as summarized in the following table: Incidence of Infusion-Related Reactions Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m. [0m
[31mAMBISOME: adverse_reactions: [0m[1;31m7[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m86[0m[31m [0m[1;31m94[0m[31m [0m[1;31m87[0m[31m Patients with fever increase of [0m[1;31m>[0m[1;31m1[0m[31mÂ°C [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m28[0m[31m%[0m[1;31m)[0m[31m Patients with [0m
[31mchills/rigors [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m42[0m[31m [0m[1;31m([0m[1;31m48[0m[31m%[0m[1;31m)[0m[31m Patients with nausea [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m18[0m[31m [0m[1;31m([0m[1;31m20[0m[31m%[0m[1;31m)[0m[31m Patients with vomiting [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m Respiratory adverse events [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m There have been a few [0m
[31mreports of flushing, back pain with or without chest tightness, and chest pain associated with Am B isome administration; on occasion this has been severe. Where these symptoms were noted, the [0m
[31mreaction developed within a few minutes after the start of infusion and disappeared rapidly when the infusion was stopped. AMBISOME: adverse_reactions: The symptoms do not occur with every dose and [0m
[31musually do not recur on subsequent administrations when the infusion rate is slowed. Toxicity and Discontinuation of Dosing In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m, a significantly lower incidence of grade [0m[1;31m3[0m[31m or [0m[1;31m4[0m[31m toxicity [0m
[31mwas observed in the Am B isome group compared with the amphotericin B group. In addition, nearly three times as many patients administered amphotericin B required a reduction in dose due to toxicity [0m
[31mor discontinuation of study drug due to an infusion-related reaction compared with those administered Am B isome. In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a greater proportion of patients in the [0m
[31mamphotericin B lipid complex group discontinued the study drug due to an adverse event than in the Am B isome groups. AMBISOME: adverse_reactions: Less Common Adverse Events The following adverse [0m
[31mevents also have been reported in [0m[1;31m2[0m[31m% to [0m[1;31m10[0m[31m% of Am B isome-treated patients receiving chemotherapy or bone marrow transplantation, or who had HIV disease in six comparative, clinical trials: Body as a [0m
[31mWhole Abdomen enlarged, allergic reaction, cellulitis, cell-mediated immunological reaction, face edema, graft-versus-host disease, malaise, neck pain, and procedural complication. Cardiovascular [0m
[31mSystem Arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, cardiomegaly, hemorrhage, postural hypotension, valvular heart disease, vascular disorder, and vasodilatation [0m[1;31m([0m[31mflushing[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: [0m[1;31m4[0m[31m [0m[1;31m11.6[0m[31m [0m[1;31m16.3[0m[31m [0m[1;31m21.5[0m[31m [0m[1;31m20.9[0m[31m Digestive System Diarrhea Gastrointestinal hemorrhage Nausea Vomiting [0m[1;31m30.3[0m[31m [0m[1;31m9.9[0m[31m [0m[1;31m39.7[0m[31m [0m[1;31m31.8[0m[31m [0m[1;31m27.3[0m[31m [0m[1;31m11.3[0m[31m [0m[1;31m38.7[0m[31m [0m[1;31m43.9[0m[31m Metabolic and Nutritional [0m
[31mDisorders Alkaline phosphatase increased ALT [0m[1;31m([0m[31mSGPT[0m[1;31m)[0m[31m increased AST [0m[1;31m([0m[31mSGOT[0m[1;31m)[0m[31m increased Bilirubinemia BUN increased Creatinine increased Edema Hyperglycemia Hypernatremia Hypervolemia Hypocalcemia [0m
[31mHypokalemia Hypomagnesemia Peripheral edema [0m[1;31m22.2[0m[31m [0m[1;31m14.6[0m[31m [0m[1;31m12.8[0m[31m [0m[1;31m18.1[0m[31m [0m[1;31m21[0m[31m [0m[1;31m22.4[0m[31m [0m[1;31m14.3[0m[31m [0m[1;31m23[0m[31m [0m[1;31m4.1[0m[31m [0m[1;31m12.2[0m[31m [0m[1;31m18.4[0m[31m [0m[1;31m42.9[0m[31m [0m[1;31m20.4[0m[31m [0m[1;31m14.6[0m[31m [0m[1;31m19.2[0m[31m [0m[1;31m14[0m[31m [0m[1;31m12.8[0m[31m [0m[1;31m19[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m2[0m[31m [0m[1;31m31.1[0m[31m [0m[1;31m42.2[0m[31m [0m[1;31m14.8[0m[31m [0m[1;31m27.9[0m[31m [0m[1;31m11[0m[31m [0m[1;31m15.4[0m[31m [0m[1;31m20.9[0m[31m [0m[1;31m50.6[0m[31m [0m[1;31m25.6[0m[31m [0m
[1;31m17.2[0m[31m Nervous System Anxiety Confusion Headache Insomnia [0m[1;31m13.7[0m[31m [0m[1;31m11.4[0m[31m [0m[1;31m19.8[0m[31m [0m[1;31m17.2[0m[31m [0m[1;31m11[0m[31m [0m[1;31m13.4[0m[31m [0m[1;31m20.9[0m[31m [0m[1;31m14.2[0m[31m Respiratory System Cough increased Dyspnea Epistaxis Hypoxia Lung disorder Pleural effusion Rhinitis [0m[1;31m17.8[0m[31m [0m
[1;31m23[0m[31m [0m[1;31m14.9[0m[31m [0m[1;31m7.6[0m[31m [0m[1;31m17.8[0m[31m [0m[1;31m12.5[0m[31m [0m[1;31m11.1[0m[31m [0m[1;31m21.8[0m[31m [0m[1;31m29.1[0m[31m [0m[1;31m20.1[0m[31m [0m[1;31m14.8[0m[31m [0m[1;31m17.4[0m[31m [0m[1;31m9.6[0m[31m [0m[1;31m11[0m[31m Skin and Appendages Pruritus Rash Sweating [0m[1;31m10.8[0m[31m [0m[1;31m24.8[0m[31m [0m[1;31m7[0m[31m [0m[1;31m10.2[0m[31m [0m[1;31m24.4[0m[31m [0m[1;31m10[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m8[0m[31m Urogenital System Hematuria [0m[1;31m14[0m[31m [0m[1;31m14[0m[31m Am B [0m
[31misome was well tolerated. Am B isome had a lower incidence of chills, hypertension, hypotension, tachycardia, hypoxia, hypokalemia, and various events related to decreased kidney function as compared [0m
[31mto amphotericin B deoxycholate. In pediatric patients [0m[1;31m([0m[1;31m16[0m[31m years of age or less[0m[1;31m)[0m[31m in this double-blind study, Am B isome compared to amphotericin B deoxycholate, had a lower incidence of hypokalemia [0m
[1;31m([0m[1;31m37[0m[31m% versus [0m[1;31m55[0m[31m%[0m[1;31m)[0m[31m, chills [0m[1;31m([0m[1;31m29[0m[31m% versus [0m[1;31m68[0m[31m%[0m[1;31m)[0m[31m, vomiting [0m[1;31m([0m[1;31m27[0m[31m% versus [0m[1;31m55[0m[31m%[0m[1;31m)[0m[31m, and hypertension [0m[1;31m([0m[1;31m10[0m[31m% versus [0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m. AMBISOME: adverse_reactions: Similar trends, although with a somewhat lower incidence, were [0m
[31mobserved in open-label, randomized Study [0m[1;31m104[0m[31m-[0m[1;31m14[0m[31m involving [0m[1;31m205[0m[31m febrile neutropenic pediatric patients [0m[1;31m([0m[1;31m141[0m[31m treated with Am B isome and [0m[1;31m64[0m[31m treated with amphotericin B deoxycholate[0m[1;31m)[0m[31m. Pediatric patients [0m
[31mappear to have more tolerance than older individuals for the nephrotoxic effects of amphotericin B deoxycholate. The following adverse events are based on the experience of [0m[1;31m244[0m[31m patients [0m[1;31m([0m[1;31m202[0m[31m adult and[0m
[1;31m42[0m[31m pediatric patients[0m[1;31m)[0m[31m of whom [0m[1;31m85[0m[31m patients were treated with Am B isome [0m[1;31m3[0m[31m mg/kg, [0m[1;31m81[0m[31m patients were treated with Am B isome [0m[1;31m5[0m[31m mg/kg and [0m[1;31m78[0m[31m patients were treated with amphotericin B lipid complex [0m[1;31m5[0m[31m mg/kg[0m
[31min Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a randomized, double-blind, multi-center study in febrile, neutropenic patients. AMBISOME: adverse_reactions: Am B isome and amphotericin B lipid complex were infused over two [0m
[31mhours. The incidence of adverse events occurring in more than [0m[1;31m10[0m[31m% of subjects in one or more arms, regardless of relationship to study drug, are summarized in the following table: Empirical Therapy [0m
[31mStudy [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m Common Adverse Events Adverse Event by Body System AmBisome [0m[1;31m3[0m[31m mg/kg/day N = [0m[1;31m85[0m[31m % AmBisome [0m[1;31m5[0m[31m mg/kg/day N = [0m[1;31m81[0m[31m % Amphotericin B Lipid Complex [0m[1;31m5[0m[31m mg/kg/day N = [0m[1;31m78[0m[31m % Body as a Whole [0m
[31mAbdominal pain Asthenia Chills/rigors Sepsis Transfusion reaction [0m[1;31m12.9[0m[31m [0m[1;31m8.2[0m[31m [0m[1;31m40[0m[31m [0m[1;31m12.9[0m[31m [0m[1;31m10.6[0m[31m [0m[1;31m9.9[0m[31m [0m[1;31m6.2[0m[31m [0m[1;31m48.1[0m[31m [0m[1;31m7.4[0m[31m [0m[1;31m8.6[0m[31m [0m[1;31m11.5[0m[31m [0m[1;31m11.5[0m[31m [0m[1;31m89.7[0m[31m [0m[1;31m11.5[0m[31m [0m[1;31m5[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: clinical_studies: The following table presents a comparison of efficacy rates among immunocompetent and immunocompromised patients infected in the Mediterranean basin who had no [0m
[31mprior treatment or remote prior treatment for visceral leishmaniasis. Efficacy is expressed as both acute parasite clearance at the end of therapy [0m[1;31m([0m[31mEOT[0m[1;31m)[0m[31m and as overall success [0m[1;31m([0m[31mclearance with no [0m
[31mrelapse[0m[1;31m)[0m[31m during the follow-up period [0m[1;31m([0m[31mF/U[0m[1;31m)[0m[31m of greater than [0m[1;31m6[0m[31m months for immunocompetent and immunocompromised patients: AmBisome Efficacy in Visceral Leishmaniasis Immunocompetent Patients No. of [0m
[31mPatients Parasite [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Clearance at EOT Overall Success [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m at F/U [0m[1;31m87[0m[31m [0m[1;31m86[0m[31m/[0m[1;31m87[0m[31m [0m[1;31m([0m[1;31m98.9[0m[1;31m)[0m[31m [0m[1;31m83[0m[31m/[0m[1;31m86[0m[31m [0m[1;31m([0m[1;31m96.5[0m[1;31m)[0m[31m Immunocompromised Patients Regimen Total Dose Parasite [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Clearance at EOT Overall Success [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m at F/U [0m
[1;31m100[0m[31m mg/day X [0m[1;31m21[0m[31m days [0m[1;31m29[0m[31m-[0m[1;31m38[0m[31m. AMBISOME: clinical_studies: [0m[1;31m9[0m[31m mg/kg [0m[1;31m10[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m100[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m20[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m mg/kg/day, days [0m[1;31m1[0m[31m-[0m[1;31m5[0m[31m, and [0m[1;31m10[0m[31m, [0m[1;31m17[0m[31m, [0m[1;31m24[0m[31m, [0m[1;31m31[0m[31m, [0m[1;31m38[0m[31m [0m[1;31m40[0m[31m mg/kg [0m[1;31m8[0m[31m/[0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m88.9[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m/[0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m TOTAL [0m[1;31m18[0m[31m/[0m[1;31m19[0m[31m [0m[1;31m([0m[1;31m94.7[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m/[0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m11.8[0m[1;31m)[0m[31m When [0m
[31mfollowed for [0m[1;31m6[0m[31m months or more after treatment, the overall success rate among immunocompetent patients was [0m[1;31m96.5[0m[31m% and the overall success rate among immunocompromised patients was [0m[1;31m11.8[0m[31m% due to relapse [0m
[31min the majority of patients. While case reports have suggested there may be a role for long-term therapy to prevent relapses in HIV coinfected patients [0m[1;31m([0m[31mLopez-Dupla, et al. AMBISOME: clinical_studies:[0m
[31mJ Antimicrob Chemother [0m[1;31m1993[0m[31m; [0m[1;31m32[0m[31m: [0m[1;31m657[0m[31m-[0m[1;31m659[0m[1;31m)[0m[31m, there are no data to date documenting the efficacy or safety of repeat courses of Am B isome or of maintenance therapy with this drug among immunocompromised[0m
[31mpatients.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I attempted to use the recipient_message tool to ask FDAHandler about the effects of AMBISOME on the risk of hip fracture."[0m[32m,[0m
[32m      [0m[32m"However, there seems to be a technical issue or misunderstanding, as I did not receive any information from FDAHandler."[0m[32m,[0m
[32m      [0m[32m"Without specific data from the FDA, I cannot provide a reliable answer regarding the effects of AMBISOME on hip fracture risk."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does AMBISOME increase or decrease the risk of hip fracture?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I attempted to use the recipient_message tool to ask FDAHandler about the effects of AMBISOME on the risk of hip fracture."[0m[34m,[0m
[34m      [0m[34m"However, there seems to be a technical issue or misunderstanding, as I did not receive any information from FDAHandler."[0m[34m,[0m
[34m      [0m[34m"Without specific data from the FDA, I cannot provide a reliable answer regarding the effects of AMBISOME on hip fracture risk."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does AMBISOME increase or decrease the risk of hip fracture?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I attempted to use the recipient_message tool to ask FDAHandler about the effects of AMBISOME on the risk of hip fracture.[0m
[1;31m2[0m[31m. However, there seems to be a technical issue or misunderstanding, as I did not receive any information from FDAHandler.[0m
[1;31m3[0m[31m. Without specific data from the FDA, I cannot provide a reliable answer regarding the effects of AMBISOME on hip fracture risk.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hip fracture-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe question was whether AMBISOME increases or decreases the risk of hip fracture. I attempted to consult FDAHandler for information on AMBISOME's effects on hip fracture risk, but due to a technical [0m
[32missue or misunderstanding, I did not receive any data from FDAHandler. Without specific FDA data, I cannot provide a reliable answer regarding the effects of AMBISOME on the risk of hip fracture. [0m
[32mTherefore, my final answer is that I do not know if AMBISOME increases or decreases the risk of hip fracture.[0m
